A federal appeals court revived part of Teva’s challenge to the Inflation Reduction Act’s Medicare price negotiation program, according to the report. The DC Circuit ruling reopened part of the case after a lower court had rejected Teva’s arguments, with the outcome carrying implications for future negotiated price disputes. The update is coming as the broader IRA litigation landscape evolves across sponsors, and as companies plan for the operational and pricing impact of Medicare negotiations. For Teva, the procedural win helps preserve at least some legal leverage even if the full case remains contested. In the near term, the ruling may influence expectations on how quickly these disputes could resolve and how much regulatory certainty companies can count on while modeling revenue under the IRA framework.